Flexion Therapeutics announced a proposed public offering of 4 million shares to raise $122.4 million to market osteoarthritis knee pain treatment Zilretta. The company recently received FDA approval for Zilretta.
Flexion Therapeutics is a specialty pharmaceutical company focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis.
Author: Lance Jepsen
For ethical purposes, I try not to hold any position in any stock I profile on GuerillaStockTrading.com unless specifically stated in the article. Owner of GuerillaStockTrading.com. Seasoned entrepreneur, investor, and writer. I love God, family, country, stock trading, economics, and helping people learn how to trade. View all posts by Lance Jepsen